26 May 2023 Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
25 May 2023 Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer
24 May 2023 Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology
13 May 2023 GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
10 May 2023 Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV
10 May 2023 HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
10 May 2023 Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease
05 May 2023 Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class β-catenin Antagonist
04 May 2023 US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
28 Apr 2023 RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine
28 Apr 2023 U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
27 Apr 2023 Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors
19 Apr 2023 Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
18 Apr 2023 Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
18 Apr 2023 Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting
18 Apr 2023 Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
17 Apr 2023 Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
17 Apr 2023 MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
17 Apr 2023 Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Com
12 Apr 2023 Moderna Announces Clinical and Program Updates at 4th Vaccines Day
04 Apr 2023 Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
31 Mar 2023 Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
30 Mar 2023 DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
27 Mar 2023 Allergy Therapeutics announces dosing of patients has commenced in Phase I PROTECT trial investigating novel peanut allergy vaccine candidate, VLP Peanut
21 Mar 2023 Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up